Chavarría BLA, Aguilar KA, Mendoza GL, Rodríguez LF, Sánchez BL, Ibarra CP, Luna SA

Language: Spanish
References: 12
Page: 78-82
PDF size: 85.00 Kb.

ABSTRACT

Stenotrophomonas maltophilia is a non-fermentative Gram-negative bacterium related with nosocomial infections especially in immunocompromissed patients. Stenotrophomonas maltophilia exhibits innate resistance to multiple antimicrobial agents. Tigecycline is considered as an alternative in the treatment of resistant strains.A clinical case from a patient with chronic renal failure in dialysis with Stenotrophomonas maltophilia peritonitis is presented. Patient received tigecycline, after one week of treatment he developed hiperkalemia and required hemodialysis. Levels of potassium returned to normality after tigecycline was suspended. Clinical curse suggest that tigecycline could be a factor that contributed to hiperkalemia.

REFERENCES

1. Gutiérrez Martínez, CA, E Reyes García y F Corona, “Stenotrophomonas maltophilia, una bacteria multirresistente”, Rev. Asoc. Mex. Med. Crit. y Ter. Int. 2007; 21 (2): 91-94.

2. Dina, A, A Yasmina, M de Donato et al., “Caracterización fenotípica y susceptibilidad antimicrobiana de cepas clínicas de Stenotrophomonas maltophilia”, Kasmera. 2005; 33 (2): 109-118.

3. Szeto, CC, P Li, C Leung, AW Yu, SF Lui y KN Lai, “Xantomonas maltophilia peritonitis in uremic patients recieving continuous ambulatory peritoneal dialysis”, Am. J Kidney Dis. 1997; 29 (1): 91-95.

4. Taylor, G, M McKenzie, M Buhannan-Chell, D Perry, L Chui y M Dasgupta, “Peritonitis due to Stenotrophomonas maltophilia in patients undergoing chronic peritoneal dialysis”, Perit. Dial. Int. 1999; 19: 259-262.

5. Baek, JE, EY Jung, HJ Kim, GW Lee, JR Hahm, KR Kang y SH Chang, “Stenotrophomonas maltophilia infection in patients receiving continous ambulatory peritoneal dialysis”, Korean J Intern. Med. 2004; 19 (2): 104-108.

6. Machuca, E, AM Ortiz y R Rabagliati, Stenotrophomonas maltophilia peritonitis in a patient recieving automated peritoneal diálisis”, Adv. Perit. Dial. 2005; 21: 63-65.

7. Bosó-Ribelles V, Romá-Sánchez E, V Salavert-Lleti M, Hernández Marti y JL Poveda-Andrés, “La tigeciclina, el primer antibiótico de una nueva clase: las glicilciclinas”, Rev. Esp. Quimioterap. 2007; 20: 19-35.

8. Curcio, D J y R E Isturiz, “Tigecilina, la primera gicilciclina”, Rev. Panam. Infectol. 2006; 8 (3): 35-42.

9. Sacchidanand, S, RL Penn, D Curcio et al., “Efficacy and safety of tigecycline monotherapy compared with vancomycin plus azteronamin patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial”, Int. J Infect. Dis. 2005; 9:251-261.

10. Ellis-Grosse, EJ, T Babinchak, N Dartois et al., “The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam”, Clin. Infect. Dis. 2005; 41 (supl. 5): S341-353.

11. Oliva, ME, A Rekha, A Yellin et al., “A multicenter trial of the efficacy and safety of tigecycline versus imipenem/ cilastatin in patients with complicated intra-abdominal infections”, BMC Infect. Dis. 2005; 5: 88.

12. Babinchak, T, E Ellis-Grosse, N Dartois et al., “The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data”, Clin. Infect. Dis. 2005; 41 (supl. 5): S354-367.